# US 2019/0315701 A1 · Novel eicosanoid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315701 A1
- Document ID: US20190315701A1
- Status: Published application
- Kind: A1
- Application number: 16/363,022
- Filed: 2019-03-25
- Published: 2019-10-17
- Earliest claimed: 2009-01-13
- Assignees: Max-Delbrueck-Centrum Fuer Molekulare Medizin; Board of Regents, The University of Texas System
- Applicants: Max-Delbrueck-Centrum Fuer Molekulare Medizin; Board of Regents of University of Texas System
- Inventors: Wolf-Hagen Schunck; Gerd Wallukat; Robert Fischer; Cosima ARNOLD; Dominik N. Mueller; Narender PULI; John R. FALCK
- Web page: https://patentgrep.com/patent/US20190315701A1

## CPC

- C07D 303/38: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/12: Antihypertensives
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07C 233/09: with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
- C07C 233/47: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 233/49: having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
- C07C 235/28: the carbon skeleton being acyclic and unsaturated
- C07C 235/76: of an unsaturated carbon skeleton
- C07C 275/14: being further substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 275/16: being further substituted by carboxyl groups
- C07C 275/20: of an unsaturated carbon skeleton
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.

## Claims

### Claim 1

A compound of the general formula (I):
or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof, wherein R1 is selected from
R2 is hydroxy, heteroalkyl, alkoxy, polyalkoxyalkyl, NR3R4, (NHS (O)2-m-(C6H4)N3, or Xaao;
R3 and R4 are each and independently of each other selected from hydrogen atom, hydroxy, alkyl, heteroalkyl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloakyl, aralkyl, or heteroaralkyl;
Xaa is Gly, a conventional D, L-, D- or L-amino acid, a non-conventional D, L-, D- or L-amino acid, or a 2- to 10-mer peptide, wherein Xaa is joined to —C(O) by an amide bond;
o is an integer selected from 1 to 10;
B is CH2, 0, or S;
m is an integer from 1 to 6;
T, U, and W are each and independently of each other selected from —CH2CH2—, and cis or trans —CH═CH—, with the proviso that at least one of T, U, V or W is —CH2CH2—;
V is cis or trans —CH═CH—:
X is absent or selected from CH, CH2, and NR5;
Z is selected from G4 CH2, and NR5′;
R5 and R5′ are each and independently of each other selected from a hydrogen atom, a hydroxy, alkyl, cvcloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aralkyl, heteroaralkyl group;
Y is —C(O)—, —C(O)—C(O)—, —O—, or —S—; and
n is an integer from 0 to 6.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is —COR2.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein m is 1.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein n is 0 or 1.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The compound according to claim 1, wherein each of T, U and W is —CH2CH2—.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein Y is —C(O)— or —C(O)—C(O)—.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein X is NR5 with R5 being a hydrogen atom, a methyl, ethyl, propyl or iso-propyl group.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein Z is NR5′ with R5′ being a hydrogen atom, a methyl, ethyl, propyl or iso-propyl group.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

A compound of the general formula (I):
or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof, wherein
R1 is —COR2;
R2 is hydroxy, heteroalkyl, alkoxy, polyalkoxyalkyl, NR3R4, (NHS(O)2-m-(C6H4)N3, or Xaao;
R3 and R4 are each and independently of each other selected from hydrogen atom, hydroxy, alkyl, heteroalkyl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aralkyl, or heteroaralkyl;
Xaa is Gly, a conventional D, L-, D- or L-amino acid, a non-conventional D, L-, D- or L-amino acid, or a 2- to 10-mer peptide, wherein Xaa is joined to —C(O) by an amide bond;
o is an integer selected from 1 to 10;
B is CH2, O, or S;
m is 1;
T, U, and W are each and independently of each other selected from —CH2CH2—, and cis or trans —CH═CH—, with the proviso that at least one of T, U, or W is —CH2CH2—;
V is cis or trans —CH═CH—;
X is absent or selected from CH2 and NR5;
Z is selected from CH2 and NR5′;
R5 and R5′ are each and independently of each other selected from a hydrogen atom, a hydroxy, alkyl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aralkyl, or heteroaralkyl group;
Y is —C(O)—, —C(O)—C(O)—, —O—, or —S—; and
n is 0 or 1.

### Claim 17 (depends on 16)

The compound according to claim 16, wherein each of T, U and W is —CH2CH2—.

### Claim 18 (depends on 16)

The compound according to claim 16, wherein Y is —C(O)— or —C(O)—C(O).

### Claim 19 (depends on 16)

The compound according to claim 16, wherein X is NR5 with R5 being a hydrogen atom, a methyl, ethyl, propyl or iso-propyl group.

### Claim 20 (depends on 16)

The compound according to claim 16, wherein Z is NR5′ with R5′ being a hydrogen atom, a methyl, ethyl, propyl or iso-propyl group.

### Claim 21

A compound of the general formula (I):
or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof, wherein
R1 is —COR2;
R2 is hydroxy, heteroalkyl, alkoxy, polyalkoxyalkyl, NR3R4, (NHS(O)2-m-(C6H4)N3, or Xaao;
R3 and R4 are each and independently of each other selected from hydrogen atom, hydroxy, alkyl, heteroalkyl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, aralkyl, or heteroaralkyl;
Xaa is Gly, a conventional D, L-, D- or L-amino acid, a non-conventional D, L-, D- or L-amino acid, or a 2- to 10-mer peptide, wherein Xaa is joined to —C(O) by an amide bond;
o is an integer selected from 1 to 10;
B is CH2, O, or S;
m is 1;
T, U, and W are each —CH2CH2—;
V is cis or trans —CH═CH—;
X is NR5 with R5 being a hydrogen atom, a methyl, ethyl, propyl or iso-propyl group;
Z is NR5′ with R5′ being a hydrogen atom, a methyl, ethyl, propyl or iso-propyl group;
Y is —C(O)— or —C(O)—C(O)—; and
n is 0 or 1.

### Claim 22 (depends on 1)

The compound according to claim 1, wherein the compound of formula (I) is selected from:

### Claim 23 (depends on 1)

A pharmaceutical composition that comprises at least one compound according to claim 1 and, optionally, a carrier substance and/or an adjuvant.

### Claim 24 (depends on 23)

A method for treatment and/or prevention of conditions and/or diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, heart failure and cardiac damage, especially cardiac arrhythmias comprising administering to a patient in need thereof the pharmaceutical composition of claim 23 in a treatment and/or prevention of conditions and/or diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, heart failure and cardiac damage effective amount.

### Claim 25 (depends on 24)

The method of claim 24, wherein the conditions and/or diseases are associated with cardiac damage.
